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ABSTRACT
Galleria Mellonella as an Alternate Infection Model for Burkholderia Species
and a Comparison of Suspension and Surface Test Methods
for Evaluating Sporicidal Efficacy
Joseph D. Thiriot
Department of Microbiology and Molecular Biology, BYU
Master of Science
Melioidosis is a neglected tropical disease that continues unabated in many countries,
particularly in Southeast Asia. There is no vaccine and antimicrobial treatment is expensive and
complicated. Virulence models are important tools used to investigate genes involved in
pathogenesis. Galleria mellonella is the larvae of the wax worm moth that has been used to
model various infections. Based on previous studies, we attempted to establish an infection
model using Burkholderia pseudomallei and Burkholderia thailandensis, a related species which
is avirulent in humans. Injections of various forms of these species (fresh and frozen) were used
to develop Kaplan-Meier plots. We also tested Burkholderia cepacia, Burkholderia
vietnamiensis, Burkholeria ambifaria, and Burkholderia multivorans to understand how they
affect the larvae. We found that larvae injected with B. pseudomallei and B. thailandensis did
not accurately model the respective infections these species cause in humans, while the other
non-virulent species did not produce disease, as expected. We conclude that G. mellonella is
not an appropriate infection model for B. pseudomallei and B. thailandensis.
Healthcare-associated infections (HAI) are on the rise, and place a heavy burden on our
healthcare system each year. Disinfectants used in healthcare settings can reduce HAIs, but first
must be evaluated for proper efficacy. To date there are few statistical models that are useful in
comparing disinfectant test methods. We conducted a head-to-head comparison of two
common test methods, suspension and surface, using Clostridium difficile spores as the test
organism. A novel statistical method was developed to evaluate which test method better
predicted disinfectant performance. An activated disinfectant that gradually lost activity over
time was used in these evaluations. Results showed that the suspension test method was less
variable, and was a better predictor of disinfectant efficacy over time.

Keywords: infection model, disinfectant test, Galleria mellonella, Burkholderia pseudomallei,
suspension test, surface test
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CHAPTER 1- Galleria mellonella as an Alternate Infection Model for Burkholderia Species
Introduction
Infection models
When researching an infectious bacterium or virus, infection models are needed to
study the infection, resultant signs, and factors involved in virulence. Accurate infection models
can help deduce the mechanisms of infection and thereby help identify treatments and other
methods that might be used to combat disease. It is important that the infection model be
technically and financially practical, and mimic human infection characteristics as closely as
possible. The first chapter of this thesis endeavors to explore a novel infection model for
various Burkholderia species.
Burkholderia
Burkholderia species are saprophytic soil dwelling bacteria endemic to South East Asia,
including the countries Thailand, Vietnam, Myanmar, and also Northern Australia. (34)
Naturally competent, they take on helpful gene clusters and pathogenic islands acquired from
their soil habitat, resulting in robust organisms that are intrinsically resistant to a wide
spectrum of antibiotics. They also possess an impressive array of pathogenic mechanisms that
allow them to invade, hide, and survive in their natural hosts. As a result of their varied
methods of pathogenicity, this genus commonly infects both plant and animal species (36).
In the Burkholderia genus, there are two main species that readily infect and cause disease in
humans and animals. Burkholderia pseudomallei infects many species, causing the disease
melioidosis in humans, while Burkholderia mallei primarily infects equestrian species, causing
1

the disease glanders. However, there are cases of disease in other species as well. The
Burkholderia cepacia complex is a set of up to 20 Burkholderia species. They are also known to
infect humans, but as they are opportunistic organisms, these cases are observed less
frequently. Infected patients usually have pre-existing lung conditions, such as cystic fibrosis or
chronic granulomatous disease, or are immunocompromised. (20) The species in this
Burkholderia cepacia complex also infect plants, and come with a variety of useful survival
traits, such as nitrogen fixation or the ability to use alternate carbon sources. Some of the
better studied species include B. multivorans, B. vietnamensis, and B. cepacia. As a genus, there
is much research to be done to understand this complex and fascinating group of species.
Burkholderia pseudomallei
B. pseudomallei infects humans, and causes the disease melioidosis. (29) Due to its wide
range of symptoms, specific antimicrobial resistance, elusive behavior relative to the immune
system, and location of natural habitat, the disease is very difficult to diagnosis and treat.
B. pseudomallei is a gram negative bacterium, with a genome split between two chromosomes.
Since it is readily found in specific soils, areas where there is increased human-soil contact
provide the bacterium opportunity to invade and establish an infection. This is often the case in
countries where daily activities take people into rural areas, such as rice paddy fields. B.
pseudomallei has been suggested to have evolved from an earlier species, Burkholderia
thailandensis, by sluffing off unnecessary genes and acquiring those needed to make humans
suitable hosts (7, 19). B. pseudomallei is transmitted often through direct contact with, or
inhalation or ingestion of contaminated water or soil. This can be through cuts and abrasions
on the skin surface that allow the bacteria access. The infectious dose for this organism is very
2

small, requiring as little as 10 CFU to establish an infection. Zoonotic transmission, sexual
transmission, and vertical transmission are all believed to be uncommon for this bacterium
(43).
B. pseudomallei uses a variety of virulence factors to infect and persist in a host. It is
also hardy in challenging environmental conditions, including a broad pH range, antibiotic
presence, nutrient deficiency, antiseptic and disinfectant treatments, and extreme
temperatures (29). In addition, it is able to overcome a variety of host innate natural defenses.
Examples are lysosomal defensins and cationic peptidases (29). While there are some
differences in virulence factors corresponding to severity and type of infection, the following
few factors are common and of particular note. B. pseudomallei’s capsule provides an
important defense against a range of phagocytic cells. The capsule is comprised of a group of 3
capsular polysaccharides. It interferes with the complement factor C3b and its ability to
opsonize the surface of the bacterium, leading to reduced levels of phagocytosis (45).
The capsule also aids in epithelial cell attachment, and has other hypothesized functions (37).
Secretion systems play on important role in many of the bacterium’s survival functions. The
Type 3 secretion system (T3SS) is particularly important, as it produces and exports effector
products into the host cell that help the bacterium to invade and establish an infection.
Examples are BopE and Bsa, which, when knocked out, leave the bacterium unable to hijack the
host cell’s actin (45). These are important virulent factors that allow the bacterium to take
control of the immune cell, and like Listeria, hide from the immune system while moving from
cell to cell without exiting the cell. This creates problems for the immune system in reaching the
bacteria directly. Type IV pili are known to be important factors for many gram-negative
3

bacteria. In B. pseudomallei, the Type IV Pilin, PilA, has been shown to aid the bacterium’s
adherence to epithelial cells (31).
Burkholderia thailandensis
B. thailandensis is typically avirulent towards humans. There are very few exceptions to
this. The following are recorded cases of B. thailandensis infection. In 1999, a 16-year old male
was treated after a motorcycle accident in Thailand. He was treated with an antibiotic regime
against B. pseudomallei and survived (23). In 2006, a 2-year old child was hospitalized in Texas,
USA after near drowning and developed a B. thailandensis infection. He survived (28). In 2013, a
67-year-old man in China was found with a chest infection after two weeks of fever. After days
of diagnostics, he was discharged at the request of family, and died 2 days later. (32). In all
three cases, the patients experienced a traumatic event, which is believed to have assisted B.
thailandensis in establishing an infection. As a result of its general avirulence in humans, B.
thailandensis is classified as a Biosafety Level 1 agent. It is also a gram negative rod found in
certain soils, but with minor and important differences from B. pseudomallei.
B. thailandensis vs B. pseudomallei
In many ways B. thailandensis and B. pseudomallei are quite similar. In culture, both
organisms produce a variety of colonial morphologies. The reason for these different forms is
yet unknown. Both species possess an innate resistance to multiple antibiotic families. They
share the same natural environment, and possess similar growth and survival characteristics.
Studies have been done to show that when cloned into B. thailandensis, the Burkholderia type
3 secretion apparatus (Bsa) causes B. thailandensis to acquire virulence similar to B.
pseudomallei (26). Due to its low health risks, lack of government regulation, lower cost to
4

research, genomic similarity to B. pseudomallei, and ease in distinguishing the difference, B.
thailandensis makes an ideal candidate to study in tandem with, and in some cases, in place of
B. pseudomallei (26). While these two species are almost genomically homologous, there are
some important differences. The most important is the lack of the ara operon in B.
pseudomallei. This operon codes for the proteins needed to assimilate arabinose, and its
presence or absence has been the main distinguishing phenotypic factor between the two
species for years. Another important difference is the lack of a capsule in B. thailandensis (13).
This may be one of the main differences in virulence known so far. Beyond this, there are other
gene clusters that have been lost or gained in the B. pseudomallei genome, thought to be
associated with evolving virulence in humans. Much research is currently being dedicated to
the understanding of additional virulence factors of B. pseudomallei, and how they contribute
to the overall virulence of this formidable pathogen.
Type 3 Secretion System
Secretion systems are protein structures embedded in the membrane of prokaryotic
cells that allow passage of proteins and other substances into the host cell to aid the
pathogen’s survival. The Type Three Secretion System (T3SS) is one of six known secretion
systems that the Burkholderia genus utilizes for pathogenicity and survival (Fig 1). In general, it
consists of three main components: the base complex, the needle, and the translocon. The base
complex forms across the inner and outer membrane, and is made up of multiple ring
structures surrounding a central rod (4). The next structure, the needle, is connected to and
protrudes from the rod. This needle is hollow, allowing secreted proteins, or effectors, passage
to the target organism. The third structural component is the translocon, or the tip of the
5

Figure 1. General overview of the structure of the Type Three Secretion
System. From Finlay et al. (81)

needle. This structure senses contact with the host cell and regulates the secretion of the
effectors (4). When properly attached to the host, a pore is formed through which effectors
pass, allowing the bacteria to disrupt, change and establish new functions in the host cell, the
goal of which is to allow persistence of the pathogen (4).
Burkholderia pseudomallei is known to have three T3SSs. T3SS-1 and T3SS-2 are not well
characterized, but are known plant secretion systems homologous to those in Ralstonia and
Xanthomonas. The T3SS-3 structural proteins are better understood, and are conserved across
other bacterial families (27).
Due to the similarity in which B. pseudomallei invades hemocytes and macrophages, we
believe that the various Burkholderia species use the T3SS-3 to invade and establish an
infection in the hemocytes of Galleria mellonella larvae (3, 30).
6

Melioidosis
Melioidosis, or Whitmore’s disease, is a systemic disease with a wide spectrum of
symptoms. This makes diagnosis difficult, and misdiagnoses are not uncommon (43). This
increases the number of deaths attributed to the disease (22). There are four major types of
infection: pulmonary, septicemic, localized, and disseminated (43). Each of these types of
infections carry distinctive symptoms. The most common disease is a pulmonary infection in
which diagnosis is problematic, as symptoms can range anywhere from those of a mild
bronchitis to those associated with a severe pneumonia. Additional symptoms include a high
fever, headache, chest pain, and can sometimes also produce muscle soreness and anorexia
(43). Localized infections are the easiest to diagnosis, as they usually manifest with swelling and
a noticeable nodule, ulcer or skin abscess. These can be accompanied by fever or mild muscle
aches (43). Disseminated infections commonly produce abscesses in the liver, spleen, lungs and
prostate (43). Finally, during a bloodstream infection, individuals may have abscesses
throughout the body, including the liver, spleen or prostate. The symptoms progress rapidly,
and can include disorientation, muscle soreness, joint pain and abdominal pain (43). Those with
diabetes or renal diseases are most affected by this type of infection, and it often results in
septic shock. The incubation time can range from a few days to years, adding another difficult
variable towards correct diagnosis. Currently there are no approved vaccines, so the public
health concern remains high (14). Previous vaccine candidates have been evaluated, and none
are currently ready for a clinical or commercial setting (14). Endemic regions of Burkholderia
include South-East Asian countries and Northern Australia, and the countries with the highest
number of reported cases of the disease are Thailand and Australia. However, this does not
7

take into account the constant problem of melioidosis underreporting, and therefore, there
may be other countries with significant mortality and infection rates (22).
Worldwide there are an estimated 165,000 cases annually, with 89,000 deaths (Fig 2,
34, 22). Mortality remains at a surprising 40%, regardless of treatment. It is believed that the
disease is underreported in as many as 79 countries. Roughly 75% of reported cases occur
during the rainy season (21). This wide reaching disease needs further research, and developing
cheap alternative virulence models is paramount to its study. Those populations most at risk
include: diabetics, people with a pre-existing lung disease or complication, people with renal
disease or complications, alcoholics, and immunocompromised patients.

Figure 2. Global evidence consensus and geographic locations of melioidosis occurrence from 1910 to 2014.

Country coloring is based on evidence-based consensus with green representing a complete consensus on
absence of B. pseudomallei and red a complete consensus on presence of B. pseudomallei. Black dots represent
geo-located records of melioidosis cases or presence of B. pseudomallei. From Limmathurotsakul et. al. (21).
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Galleria mellonella
G. mellonella larvae can be found worldwide (46). In the past decade, increasingly more
research has found this organism to be a useful alternative virulence model for bacterial, viral
and fungal invasion, as well as for bacteriophage, toxin and other therapeutic treatments (25,6,
39, 40). It possesses a number of advantages over traditional mammalian virulence models. The
financial input to set up and maintain a constant G. mellonella stock is far less than a rodent
model, and there are no regulatory bodies that limit experimentation (47). They do not require
feeding or other routine care, and can be housed for weeks until
needed (25, 35). The cheap aspect of their breeding and maintenance allows high-throughput
testing, providing the option for higher statistical weight. The larvae can be kept at 37°C, which
provides an environment conducive to the human body and the optimal growth temperature
for many pathogens. Due to their size, a precise inoculum of bacteria can be injected without
difficulty or concerns of variability. The larvae possess a basic but similar innate immune system
to humans, allowing limited but easy comparisons for early studies of virulence factors and
treatments. Their immune system is comprised of an innate response, providing an assortment
of phagocytic cells, nodulization and large scale encapsulation, melanization, haemolymph
clotting, and anti-microbial peptide production (41).

9

Figure 3. A larvae of the Greater Wax Moth, Galleria mellonella. Nodulation has begun to
occur, as seen from the black splotches on the lower half of the larvae.

The primary immune cell of the larvae, hemocytes, are surprisingly similar in cellular
structure and function to mammalian phagocytes. There are at least 8 types of hemocytes
known, each with specific function and purpose (41). Some of the similarities are as follows;
during a cellular immune response, hemocytes are able to differentiate between self and nonself. The phagocytic cell’s activity is activated by the process of opsonization, utilizing
complement-like proteins. Insect cells also produce a superoxide after a pathogen is engulfed
due to a membrane-bound enzyme system being activated. Hemocytes possess surface
receptors, allowing pathogen recognition. Nodulation, the binding of hemocytes to bacteria to
form clusters, is the primary defense mechanism (Fig 3). Once complete, melanization of the
nodules will occur (Fig 4). While this is not the same process as in humans, the complement
pathway used is similar (41). Table 1 shows the similarities between hemocytes and
neutrophils relative to the innate immune response.
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Table 1. Summary of similarities between insect hemocytes and human neutrophils. From
Browne et. al (41)

Hemocytes

Neutrophils

Phagocytosis

Lectin-mediated

Lectin-mediated

ROS

O2−, H2O2, NO−

O2−, H2O2, NO−

Degranulation

Yes

Yes

AMPs

Peroxynectin, transferrin,
lysozyme, defensins

MPO, transferrin,
lysozyme, defensins

Receptors

TLRs, B-1,3-glucan, IL-IR

TLRs, B-1,3-glucan, IL-IR

Transcription factors

NFκB, IκB

NFκB, IκB

Cascades

IMD, JNK, JAK-STAT

IMD, JNK, JAK-STAT

Kinases

p38 MAPK, ERK, PKC, PKA

p38 MAPK, ERK, PKC,
PKA

Neutrophil extracellular
traps (NET)

NET-like structures
present

NETs present

Previous G. mellonella model use with Burkholderia
Table 2 shows studies in which G. mellonella has been used to model infections with B.
thailandensis and B. pseudomallei. In the few studies that have been performed, there is
considerable variation in the survival percentages, revealing the need for further studies to
better establish this model.
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Table 2. Studies that used G. mellonella as a model for B. thailandensis and B. pseudomallei infections in the
last 10 years.

Species and Strain
B. thailandensis
E264
E264
E264
E264
CDC2721121
CDC2721121
B. pseudomallei
K96243
K96243
K96243
K96243
K96243
K96243
K96243
K96243

Concentration
CFU/ml

Survival (%)

Time post
Source
injection(hrs)

10
102
102
103
102
104

100
90
50
3
0
0

24
24
24
24
24
24

This study
This study
3
This study
3
6

10
10
102
102
103
103
104
104

<20
100
0
77
50
0
30
0

48
24
24
24
24
24
24
30

10
This study
3
This study
5
This study
16
16

G. mellonella is a cheap and efficient infection model for B. pseudomallei and B.
thailandensis that gives an accurate representation of human infection.
Materials and Methods
Bacterial strains and culture growth
All bacterial strains were grown in/on LB nutrient broth and agar unless specified
otherwise. All strains were obtained from the American Type Culture Collection (ATCC),
Manassas, VA, excluding B. pseudomallei K96243, which was obtained from The National
Collection of Type Cultures (NCTC), London, UK. The fresh injection inoculum for the various
strains was prepared by inoculating 5ml LB broth with an isolated colony, and incubated at 37°C
with shaking at 200 rpm. After ~18 hours, 100µl was added to a fresh 5ml tube of LB broth,
12

which was incubated at 37°C with shaking at 200 rpm until an OD600nm of 0.1 was reached. Serial
dilutions were performed in PBS to reach the desired CFU/ml. Spread plates from these
dilutions were performed in three independent tests to obtain viable counts at 0.1 OD600nm.
For frozen inoculation suspensions, a 5ml LB broth was inoculated with an isolated colony and
incubated at 37°C and shaken at 200 rpm for ~18hrs. From this culture, 100 µl was used to
inoculate a 5ml LB broth subculture. This was grown into log phase and serial dilutions were
performed in 15% glycerol and PBS. Stocks of 100 µl aliquots were created and stored at -80°C.
After one week, three stocks were thawed and viable concentrations were assayed by further
dilution and spread plating, followed by incubation at 37°C for 48hrs, and colony counting.
Galleria mellonella care and injection
Galleria mellonella larvae were purchased from Best Bet Waxworm, MN, and
maintained at 15°C in the dark until injection. Larvae were used within 2-3 weeks after
purchase. Larvae were injected in the left upper proleg, using a 50µl Hamilton gas syringe with
10 µl of inoculum. Death was scored by observed darkening due to melanization and/or no
movement after gentle manipulation. Controls for needle trauma, carrier used, and injection
location on larvae were performed. Briefly, 10 µl PBS was injected into 10 larvae and death
over time was recorded. Larvae were also injected in their lowest left proleg. If any of the
controls died, the results from this test were discarded.
Statistical Analysis
The statistical software GraphPad was used to create the Kaplan-Meier graphs, bar
graphs, to perform the t-tests, and the Wilcoxon signed-rank tests.
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Results

A.

B.

Figure 4. Example of larvae beginning nodulization, resulting in melanization of
individual segments. A) Larvae mostly still healthy, with some nodulization (red arrows).
B) Complete melanization of larvae, resulting in death.
Infection of G. mellonella with B. pseudomallei
Two types of B. pseudomallei were prepared for injection, fresh and frozen stocks. The
frozen suspensions produced a uniform increase in time for an LD50 as the concentration of
inoculum decreased, roughly two more hours for every ½ log decrease in inoculum (Figure 5).
These were 1,000 CFU at 24hrs, 500 CFU at 26hrs, 100 CFU at 28hrs, 50 CFU at 30hrs, and 10
CFU at 36hrs. Likewise, with the fresh B. pseudomallei suspension, the survival curves followed
a similar pattern, but did not result in the same LD50 values as the frozen stocks. They reached
the LD50 in less time. Values were 1,000 CFU at 20hrs, 100 CFU at 26hrs, and 10 CFU at 30hrs.
Figure 5C shows a comparison of the two suspension types at 1000 CFU. Using the Wilcoxon
signed-rank test, we find that there is a highly significant difference in LD50 between the
suspension types (p = 0.0005).
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A.

B.

C.

D.

Figure 5. Survival of G. mellonella larva injected with various concentrations of B. pseudomallei. Two suspensions of
B. pseudomallei were prepared, fresh and frozen. At least 90 separate larvae were infected at each CFU concentration
and their death rates were averaged to calculate the survival curves. A) G. mellonella infected with fresh inoculum of B.
pseudomallei. B) G. mellonella infected with frozen inoculum of B. pseudomallei. C) Kaplan-Meier survival curve
comparison of fresh and frozen suspensions of B. pseudomallei at 1,000 CFU. D) Bar chart comparison of % survival
using the two suspensions of B. pseudomallei at 1,000 CFU. **** denotes P value < 0.0001 using the Wilcoxon signedrank test.

Infection of Galleria mellonella with B. thailandensis
Fresh and frozen suspensions of B. thailandensis were prepared and injected into G.
mellonella. Similar to the B. pseudomallei results, B. thailandensis caused the larvae to die in
the same pattern. In Figure 6A we see after inoculation with the fresh stocks, the larvae reach
an LD50 4-5hrs later as the CFU decreases by a log. In Figure 6B we find the frozen stocks of B.
thailandensis follow the same trend. Beginning with 1,000 CFU at the LD50, there is a consistent
15

delay of 6hrs added as the CFU dropped one log. Interestingly, there was only a 2hr increase in
time to reach the LD50 when the CFU dropped half of a log.
A.

B.

C.

D.

Figure 6. Survival of G. mellonella larva injected with various concentrations of B. thailandensis. Two
suspensions of thailandensis were prepared, fresh and frozen. ≥90 separate larvae were infected at each CFU
concentration and their death rates were averaged to calculate the survival curves. A) G. mellonella infected with
fresh inoculum of B. thailandensis. B) G. mellonella infected with frozen inoculum of B. thailandensis. C)
Kaplan-Meier survival curve comparison of the fresh and frozen suspensions of B. thailandensis at 1,000 CFU.
D) Bar chart comparison of the two suspensions of B. thailandensisi infected with 1,000 CFU. **** denotes P
value < 0.0001 using the Wilcoxon signed-rank test.
Comparison of G. mellonella survival between species
When injected with the fresh inoculums of both species there was a statistically
significant difference in survival of larvae (Figure 7A, B). Interestingly, unlike the fresh stocks,
the frozen stocks did not show any statistical difference at the LD50 between B. pseudomallei
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and B. thailandensis (Figure 7C, D).
A.

B.

D.

C.

Figure 7. Kaplan-Meier survival curves and bar charts of G. mellonella infected with Burkholderia. A)

Comparison of G. mellonella death after injection of B. pseudomallei and B. thailandensis fresh suspension.
B) Bar chart comparison G. mellonella death after injection of B. pseudomallei and B. thailandensis fresh
suspension. C) Comparison of G. mellonella death after injection of B. pseudomallei and B. thailandensis
frozen suspensions. D) Bar chart comparison G. mellonella death after injection of B. pseudomallei and B.
thailandensis frozen suspension. **** denotes P value <0.0001 using the Wilcoxon signed-rank test.

Species from the B. cepacia complex
Further injections of G. mellonella were performed using species from the B. cepacia
complex, to evaluate their effects with this model. None of these species produced an LD50
within a reasonable length of time. These results were expected and are consistent with their
reported virulence in other animals and humans (Figure 8).
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A.

B.

C.

D.

Figure 8- Kaplan-Meier survival curves of Galleria mellonella injected with various

Burkholderia cepacia complex species. A) Survival of G. mellonella injected with B. multivorans.
B) Survival of G. mellonella injected with B. vietnamiensis. C) Survival of G. mellonella injected
with B. ambifaria. D) Survival of G. mellonella injected with B. cepacia.

Discussion
A cheap alternative pathogenesis model for the study of Burkholderia would enhance
the research efforts of scientists attempting to develop vaccines and treatments for those in
endemic areas. We have expanded the efforts of other labs in attempting to use G. mellonella
as a viable model to evaluate virulence for the Burkholderia species. Figure 5 showed that the
difference in suspension preparation can cause a statistically significant difference in survival
time of the larvae. We observed that larvae infected with the fresh suspension died 2-4 hours
faster than those infected with the frozen suspension, at all CFU levels. This may be due to the
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stress-induced effects of freezing on the bacteria, which could have affected their virulence
capabilities. While not investigated at the molecular level, this concern was considered by
Chantratita et al. when characterizing morphology types of B. pseudomallei, and the effect
freezing had on their morphological changes (38). Figure 5 also showed that by 24 hrs postinjection (pi), no G. mellonella infected with 1,000 CFU of B. pseudomallei survived. A study in
2011 by Vanaporn et al. showed that 50% of their larvae remained alive using the same
parameters (10). Further conflicting data from Muller et al. showed that 30% of larvae
remained alive after 24 hrs pi with a log higher infection inoculum of 104 (16). In Figure 5, 77%
of larvae infected with 100 CFU B. pseudomallei remained alive at 24hr pi, whereas a study in
2011 by Wand et al. found none survived using these same parameters (3). The causes for
these differences are hard to identify, since much effort was made in this work to follow the
methods of previous studies in order to maintain the consistency of the model.
B. thailandensis mirrored the same trend as observed for B. pseudomallei. Figure 6 shows
results for the fresh and frozen prepared suspensions. There was a statistically significant
difference between the Kaplan-Meier curves of the frozen and fresh 1,000 CFU B. thailandensis
infections. While there are fewer studies with B. thailandensis in the literature, we saw the
same variability. We show that at 24 hrs pi with 100 CFU, there was a 90% survival rate (Figure
6A), while Wand et al. showed a 50% survival using the same parameters (3). Again, there are
conflicting finding from the current studies available.
We showed that with fresh suspensions at 1,000 CFU, there was a statistically significant
difference between B. thailandensis and B. pseudomallei at 24 hrs pi (Figure 7A). While the
difference in survival rates of larvae injected with fresh B. pseudomallei and B. thailandensis
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(Figure 7A) was significant, it carries with it serious practical issues. The window of time
between both populations succumbing to infection and death is only about 2 hrs. This leaves a
small margin with which to experiment with virulence mutants, and may restrict the impact of
otherwise promising findings. Surprisingly, with frozen prepared suspensions at the same
parameters, there was no statistical difference (Figure 7C). Again, we hypothesize that the
damage caused by freeze/thaw may have affected the bacterium’s virulence capabilities, and
delayed the death of the larvae infected.
Infections of G. mellonella with species from the B. cepacia complex did not yield
noticeable kill within the tested time frame (Figure 8A-D). This is consistent with other studies
using the same infection model (8, 9, 18). These species are not able to establish an infection in
healthy humans easily, and most clinical cases are in cystic fibrosis or otherwise
immunocompromised patients (9).
Previous studies have been performed to test the usefulness of G. mellonella as a
virulence model for the Burkholderia species. The literature on this topic is limited in a number
of ways. These limitations restrict the implications of their conclusions, making them less
robust. These factors include: amount of data reported, length of survival experiment ( many
were terminated prematurely), lack of challenge variability, lack of Burkholderia species tested,
and small population size tested. We have taken these factors into account, as well as others to
improve upon and add to this virulence model. Additional variables that we included in our
testing beyond those stated were age of larvae at time of injection, incubation temperature of
larvae post injection, temperature of inoculation preparation, frozen vs. fresh inocula, sterility
of larvae pre-injection, and standardization of CFU in the inocula. We found no difference in
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survival rates between disinfected vs. non-disinfected larvae pre-injection (data not shown).
The temperature of incubation post injection had a large effect on survival of larvae (data not
shown). This is assumed to be due to the bacteria not being at their optimal growth
temperature, and thus not replicating or producing the proteins needed for establishing an
infection in the larvae.
It was interesting to note the patterns of death produced by different species of
Burkholderia. Both B. thailandensis and B. pseudomallei exhibit kill in which one to three larvae
die due to infection after at least 10 hours. This is followed by the majority of larvae suddenly
dying, with up to 80% of larvae deceased within a 2-hour period. Finally, any remaining larvae
that were holding out succumb to the infection and die within a few hours more. This pattern
was very consistent and reproducible. While more research must be done, we can hypothesize
about what is causing the sudden death of the larvae. One train of thought follows the notion
that there is an established point at which a certain level of melanization causes the larvae to
simply shut done, no longer able to maintain organ functionality. This is confirmed visually as
the larvae increase in nodulization and black pigmentation up to the point that they die.
Another contrasting view is that at a certain time point, the bacteria are able to freely roam
through the larvae, causing a systemic infection. This hypothesis would help explain the larvae
which do not follow the traditional pattern of increasing in discoloration up to death. We found
that there were occasional larvae that not only showed a lack of melanization at death, but
were still ‘healthy’ looking according to the color. (These larvae were confirmed dead after
gentle manipulation) Whatever the cause, there was a clear pattern of infection and
reactionary behavior from the larvae.
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As a model organism, G. mellonella is becoming more frequently used for the benefits
stated previously. The greatest problem with this model is the lack of standardization of
important factors involved in rearing, care, and injection of the larva. In their review, Cook et al.
discussed the ramifications of a lack of genetic data, stating the negative outcome of, “genetic
variability or epigenetic difference between populations on experimental outcomes.” (35) Since
there are a variety of locations from which these larvae may be acquired, and labs can rear
them in disparate ways, differences in larvae will continue to be a significant variable (35).
Tinsley et al. showed that genetic variations in populations of D. melanogaster caused varying
susceptibility against some microbial pathogens (42). These factors could be a reason for the
conflicting results many of the studies have produced. For now, it would be hard to establish
one genetically stable population as this model is used internationally and one source of the
larvae would negate the advantage of being able to obtain them cheaply and quickly.
Conclusion
We have found that G. mellonella was not an accurate representative of human
infection for B. pseudomallei and B. thailandensis. These findings come contrary to previously
published studies, which state that this model follows the natural human infection response
against members of the Burkholderia genus.
Author Contributions
Experiments were performed by Joseph Thiriot and Taalin Rassmussen. Thesis was
written by Joseph Thiriot. Experimental design, experiment performance and editing of thesis
was overseen by Richard Robison.
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CHAPTER 2- A comparison of Suspension and Surface Test methods for evaluating sporicidal
efficacy
Introduction
Nosocomial Infections
Each year a discouraging number of patients acquire a healthcare-associated (HAI) or
nosocomial infection while visiting the hospital. Roughly 1.7 million HAIs are reported in
hospitals around the US each year. These infections cause 99,000 deaths, and ~$20 billion
additional healthcare related expenses (68). This heavy burden on our healthcare system, and
staggering number of preventable deaths, is a grave concern for all involved in the healthcare
industry. The number of deaths here is truly worrying, as it towers over other disease-related
mortality rates each year, such as pneumonia deaths at 51,811, HIV at 6,465, Hepatitis A-C at
7461, and flu deaths of >80,000 during the past 2017-18 season (69,70). The government has
made noticeable efforts to reduce these numbers, and in 2009 initiated the ‘National Action
Plan to Prevent Health Care-Associated Infections: Road Map to Elimination’ (79). This plan
outlines five year goals for various parties to work towards in a collaborative effort. Despite
these efforts, and the positive changes we have seen so far, further efforts are needed to
prevent these infections. One approach is the improvement of disinfectants used in the hospital
environs and on equipment that comes in contact with patients.
Disinfectant Testing
Before a product can be used in a Health Care setting it must first undergo rigorous
testing to ensure its efficacy, and to fully understand any safety issues it presents to the
environment and personnel. As such there is a need to have tests that correctly and accurately
evaluate a given disinfectant. To date there is no international governing body that controls the
23

regulation of such products, and there is no set standard testing used throughout the world. As
a result, there are many different methods used to test the efficacy of disinfectants. However,
some nations have methods approved and enforced, such as the USA, which are enforced by
the Environmental Protection Agency (EPA) and Food and Drug Administration (FDA). The wide
range of test methods can be separated broadly into three categories: Suspension, Carrier, and
Surface tests (64). There are different tests within these three categories, but our primary focus
will be on the broad categories. As will be discussed, each carries benefits and weaknesses.
Each method provides a different look into the usefulness of a given disinfectant against the
chosen organism under various conditions.
Suspension Method
Suspension tests are the most basic of the three, and provide the best full contact
between the disinfectant and the challenge organism. Briefly, an aliquot of a defined bacterial
suspension is added to a known volume of liquid disinfectant, which is immediately mixed. At
this point there is also the option of adding a soil load (55). After specified contact times, an
aliquot of the mixture is added to a tube of neutralizer, thereby stopping disinfectant action.
The suspension is assayed for viable organisms via serial dilution and various plating methods,
including membrane filtration. Colony forming units (CFUs) are counted and a reduction factor
is calculated. A current Suspension Method example is BS EN 13704 (75). The advantage of this
method is the unimpeded and intimate contact between the disinfectant and the organism,
allowing for maximum disinfectant activity. Because of this, suspension tests tend to be much
more reproducible, and provide a truer picture of the disinfectant kill kinetics (55). It lacks,
however, simulation to a plausible real-life situation in which the conditions would be similar.
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Carrier Method
The Carrier Method involves small carriers (penicylinders) of various material (glass,
metal, porcelain) that are suspended in a solution containing the challenge organism for a set
time period. These now contaminated carriers are allowed to dry, then submerged in
disinfectant for a specified time. Once removed from the disinfectant solution, they are placed
in nutrient broth and incubated to verify kill of all challenge organisms (55). For kill to count, no
organism can be found in the tube, which will be manifest by clear broth after incubation (76).
This method is currently used frequently in the US, named the AOAC Use-Dilution Test, MB-0514 (76). Due to the short contact time and the need to penetrate a dried biofilm, the
antimicrobial solution needs significant biocidal activity, ensuring a high quality disinfectant.
One can test many penicylinders in the same test. This method also has weaknesses. There is
some statistical variability due to the test not requiring all carriers to pass for it to be counted
as a pass test. Any physical variation in the carriers that give the challenge organism an edge to
survive may be the cause of a failed tube. The test is hard to perform, and unskilled workers
may produce false positives if not trained well or have achieved sufficient skill and experience
(55).
Surface Method
In general, this method consists of taking a known volume of challenge organism and
drying it on a surface, such as a small disk. Surface disks have long been used by the EPA and
federal institutions of other countries in a standardized test method to measure the efficacy of
disinfectants. These disks can be made of different materials, including plastic, metal and
porcelain (55). The test procedure is as follows: an aliquot of an organism suspension with a
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pre-determined concentration is placed on the disk and allowed to dry. The test disinfectant
treatment is applied directly to the dried organisms on the disk, which is allowed to sit for the
test contact time. Once completed, neutralizer is added to stop all disinfectant activity. This
solution is assayed for viable organisms via serial dilution and a suitable assay for viable
organisms like membrane filtration. This method has advantages over others such as its closer
simulation of actual disinfection applications, and as a result, has gained acceptance over the
other two test methods. Due to the process of drying organisms such as spores on the disk
before treatment, this method represents a typical disinfectant to spore encounter on an
environmental surface. In this regard the surface test gives us the best representation of how a
disinfectant will perform under actual use conditions. However, there are limitations. The
surface disks, while very similar, are never exactly the same. This is particularly true with
stainless steel, where there is a brushed finish to the surface. Due to the variability of the brush
pattern on each carrier and the unique way in which the spores dry on the carrier, there will
likely always be slight differences in the nature of the dried spore films (64). Because of this, the
reproducibility of this test suffers, and a standard is hard to establish. Surface-based methods
are also inherently more variable because they involve at least two kinetic events: penetration
of the dried biofilm by the disinfectant followed by its killing actions.
Spores
Endospores, or spores, are a non-reproductive, dormant stage that some bacterial
genera produce to ensure their survival during harsh conditions (63). They are induced to form
by external and environmental pressures, such as a lack of nutrients and water (62). Spore
formation is most often a trait of some gram-positive rods. Spores can survive in their dormant
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state for thousands of years. Due to their hardy nature, they become much more of an issue
when found in any healthcare setting, as they require harsher disinfectants to affect the
necessary kill.
Spore Attributes and Structure
Spores are very resistant to environmental stresses and chemical control measures,
including extremes in temperature and pH, salinity, UV radiation, desiccation, and chemical
disinfectants (63). This is due in large part to their structure. Spores are generally comprised of
the following layers: exosporium, spore coat, outer membrane, cortex, germ cell wall, inner
membrane, and core. However, there are exceptions to this order.

Figure 9. Spore structure. A representation of a ‘typical’ bacterial
spore (structures not drawn to scale). Modified from Setlow
(2006). -From Leggett et. al. (49)

Exosporium
The exosporium is the outer layer of Clostridium difficile spores. It is composed of
protein (43-52% dry weight), carbohydrates (20-22% dry weight), and lipids (15-18% dry
weight), with small amounts (~4%) of calcium and magnesium (49). In the context of clostridia,
much remains to be studied to fully understand their spore structure. This is the layer that any
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disinfectant will encounter once it gets past the biofilm and extracellular matrix build up. Up to
now, it does not appear that the exosporium aids greatly to its chemical resistance (49).
Spore Formation
The formation of the endospore from a vegetative state is a survival tactic, and can
occur for a variety of reasons. Once formed, the spore has the ability to remain inactive, or to
reactivate into its vegetative state (80). Again, this is the result of external factors, like the
sudden availability of nutrients. Figure 10 depicts the different phases of an endospore
formation. While this is the norm, there are exceptions to this order of events among different
bacteria (80).

Figure 10. Key morphological changes that take place during sporulation.

Modified from McDonnel (2007). From Leggett et. al. (49)

Current Statistical Models
To date there is a lack of statistical modelling for disinfectant testing in the literature.
Some studies have tried to approach their analysis through tests of reproducibility for an
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individual method. Others, to provide a statistical method to determine the pass-error and failerror rates of the standardized Use Dilution Method (71). Another approach has been to
develop a statistical model to establish the error rates of studies involving multiple laboratories
and/or organisms (72, 74). These studies are important in providing statistical transparency and
credibility to methods that are currently used, or that are being proposed for future use. They
help in the essential role of reproducibility among different laboratories. While these are
important studies, very little has been done in comparing different methods, and creating a
statistical model to calculate their ability to assess a product successfully. In light of this
absence, this study explores a novel statistical approach to compare the two methods of
suspension and surface testing.
Materials and Methods
Spore Preparation
A test suspension containing endospores from C. difficile (ATCC #43598) was prepared
following the US EPA procedure MB-28-01 (30). Briefly, an isolated C. difficile colony was used
to inoculate 10 mL of pre-reduced Reinforced Clostridium Medium (RCM) broth, which was
incubated anaerobically for 24 hr at 37 °C. From this culture, lawns were created on CDC
Anaerobic Blood Agar (CABA) plates and grown anaerobically for ten days at 37 °C. The spores
were harvested from each CABA plate by scraping them into suspension. The resultant
suspension was centrifuged to pellet the spores. Spores were re-suspended in sterile PBSTween 80 solution. This centrifugation/resuspension process was repeated a total of three
times. The spore suspension was then placed at 65 °C for 10 min to kill vegetative organisms,
and the spores were purified using a HistoDenz (Sigma Aldrich, St. Louis) gradient. The final
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viable C. difficile spore suspension was ascertained to be 1.11 x 108 spores/mL by serial dilution
and colony growth on CABA plates. It was greater than 95% spore purity as determined by
phase-contrast microscopy. The final spore suspension was stored at 4 °C until used.
Disinfectant Solution
A peracetic acid-based disinfectant was activated on Day 0 of the testing following the
manufacturer’s instructions. Briefly, the inner cap was compressed, releasing part B into part A.
The 2 solutions were mixed thoroughly by repeatedly inverting the bottle. This same bottle of
disinfectant was used throughout these studies, and evaluated as it decayed with age.
Neutralization Solution
The following neutralizer formulation was made fresh each day and used for both the
surface and suspension tests. The Neutralizer solution consisted of 12.7% Tween 80, 6.0%
Tamol SN, 1.7% lecithin, 1% Peptone, 1.0% Cysteine and 500 mM Tris (pH 7.0). The neutralizer
was sterilized by autoclaving. For the carrier test, 10 ml of neutralizer was used per carrier,
while 9 mL of neutralizer was used per tube for the suspension test.
Suspension Test
A 9.9 ml aliquot of the disinfectant was added to a sterile 50 ml polypropylene centrifuge
tube. These tubes were equilibrated in a 20 °C water bath. Then, 0.1 ml of the C. difficile spore
suspension was added at time zero. After the specified contact times (1, 2, and 5 min), 1 ml of
this mixture was added to 9 ml of neutralizer. The tube was mixed thoroughly. After two min,
the neutralized suspension was serially diluted in sterile 9-ml physiological saline solution (PSS)
blanks. The number of viable organisms in selected dilution tubes was assayed by membrane
filtration. One ml aliquots were plated in triplicate. The membranes were washed with about
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100 ml of sterile PSS and removed to FA-HT plates (Fructose agar with horse blood and
taurocholate). The plates were incubated at 37 °C for 72 hours under anaerobic conditions
(ANOXOMAT system). The number of colonies on each filter was counted and log reduction and
percent kill values were computed.
Surface Test
The ASTM E2197-11 protocol was followed (78). Briefly, the surface test consisted of the
following steps. Ten µl of the spore suspension (containing approximately 106 spores) was
deposited onto each carrier and the carriers were dried under vacuum in a desiccant chamber.
At time zero, 50µl of the disinfectant was added to an inoculated carrier in a flat-bottom vial.
After the specified contact time (5 min), 10 mL of neutralizer was added to the vial, and the vial
was vortexed for 45-60 sec. The number of viable organisms released from the carrier were
assayed by membrane filtration by pouring the entire contents of the vial into the funnel, and
washing the vial with 10 mL of PSS three times. The membranes were placed on FA-HT plates.
The process of preparing a disk and testing it thus far was repeated an additional nine times for
a total of ten replicates. The plates were incubated at 37°C for 72 hours under anaerobic
conditions (ANOXOMAT system). The number of colonies on each filter was counted and log
reduction and percent kill values were computed.
Controls
Surface Test
An estimate of the number of viable spores present on a disk was computed by performing
membrane filtration assays on selected 1:10 dilutions in PSS, on a vial containing 1 inoculated
dried disk treated with 50µl PSS and 10 ml of neutralizer, and vortexed in an identical manner
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to the disinfectant-treated disks. These controls were plated in triplicate.
A disk sterility control was completed by performing membrane filtration assays
of a vial containing 50 ml of disinfectant applied to a sterile disk, and 10 ml of neutralizer. The
entire contents of the vial were poured into a funnel with a membrane. The vial was rinsed with
10 mL of PSS three times.
Suspension Test
An estimate of the number of viable spores used in the suspension test was computed by
performing membrane filtration assays on selected 1:10 dilutions in PSS of the spore
suspension.
A neutralizer control for the test disinfectant was performed by inoculating a mixture of 9.0 ml
of neutralizer and 1.0 ml of test disinfectant with 0.1 ml of the 1:1x105 (from day 0 to 3) or
1:1x104 (from day 4 to 25) dilution of the test suspension, which was then allowed to stand for
20 minutes prior to dilution and assay by membrane filtration using triplicate 1 ml samples.
Results
Log reductions of the suspension method at various contact times
Within the first 2 days of the testing, the disinfectant experienced a significant drop in
sporicidal activity (Figure 11). This was expected, as the disinfectant efficacy begins gradual
degradation. After this time point, the log reduction values exhibited decay at a significantly
slower rate. At day 10, a noticeable decline in activity with time was seen with the 1 and 2-
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minute contact times. The log reductions effected by a 5-minute contact time were consistent
until day 15, after which a steep decline was noted.

Figure 11. Log Reduction of C. difficile spores after disinfectant
treatment using a suspension method. Three contact times were
performed over 23 days. The same disinfectant solution was used.
A comparison of log reduction values obtained by suspension vs. surface methods
The log reduction values obtained from the surface method increased during the first 3
days (Fig 12). This was not expected. These values then decreased steadily until day 10, at
which point the values increased slightly until day 15. After day 15, there was a steady decrease
in activity with time until the termination of the experiment.

Figure 12. Log Reduction of C. difficile spores after disinfectant
treatment. Surface and suspension methods are compared using a 5minute contact time. The same disinfectant and spore solutions were
used in both methods throughout the experiment.
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The log reduction values obtained from the suspension method remained fairly steady
with only slight fluctuations (<0.5 log reduction) up until day 12. After this time point, there was
a steady decline in activity with time.
Statistical Analysis
A log linear model with Poisson distribution was attempted to model the colony counts
from the two test methods. In particular, we modeled the log reduction of the colony counts,
𝑁𝑁

−𝑙𝑙𝑙𝑙𝑙𝑙 𝑁𝑁 , using the number of days passed after the disinfectant was activated for the carrier
0

test. We modeled the same type of log reduction using the number of days passed after the

disinfectant was activated and contact time of the disinfectant with the spores. Please note
that 𝑁𝑁 represents the observed count of the colonies under the experimental conditions, such

as on which day and with what contact time, and 𝑁𝑁0 represents the count of the colonies which

we obtained through the corresponding control tests. The following two paragraphs describe
the models that are obtained by SAS PROC GENMOD.
For the surface test with 5-minutes contact time, we obtain that
−𝑙𝑙𝑜𝑜𝑔𝑔

𝑁𝑁
= 3.8275 − 0.0531 ∗ 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
𝑁𝑁0

where 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 are the number of days passed after the disinfectant was activated. It suggests

that with every one day passed, the log reduction was reduced by 0.0531, and the log reduction
of the disinfectant on day 0, the estimated log reduction of the number of colonies is estimated
to be 3.8275.
For the suspension test with 1-minute contact time, we obtain that
−𝑙𝑙𝑙𝑙𝑙𝑙

𝑁𝑁
= 0.8388 − 0.0331 ∗ 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
𝑁𝑁0
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This suggests that with every one day passed, the log reduction was reduced by 0.0331, and the
initial log reduction of the disinfectant on day 0 is estimated to be 0.8388.
For the suspension test with 2-minute contact time, we obtain that
−𝑙𝑙𝑙𝑙𝑙𝑙

𝑁𝑁
= 2.8181 − 0.1074 ∗ 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
𝑁𝑁0

This suggests that with every one day passed, the log reduction was reduced by 0.1074, and the
initial log reduction of the disinfectant on day 0 is estimated to be 2.8181.
For the suspension test with 5-minute contact time, we obtain that
−𝑙𝑙𝑙𝑙𝑙𝑙

𝑁𝑁
= 6.1891 − 0.1750 ∗ 𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷
𝑁𝑁0

This suggests that with every one day passed, the log reduction will reduce 0.1750, and the
initial log reduction of the disinfectant on day 0 is estimated to be 6.1891.
Comparison of predicted log reduction values versus actual log reduction values
Using the formulae obtained from the statistical analysis, the predicted log reduction
values over time were plotted against the observed log reduction values. In both suspension
and surface methods we see that the predictive model strongly followed the observed values
(Fig 13A, B). However, the surface method values had much greater variability compared to the
predicted values than did the suspension values (Fig 13B).
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A.

B.

Figure 13. Predicted and observed log reduction values plotted against time(minutes) for A). the

suspension method at all three contact times, and for B). the surface method at the 5-minute contact
time. Lines denote predicted values and circles the observed values. Predicted values were obtained
from the SAS PROC GENMOD statistical analysis software.
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Discussion
Understanding the benefits and weaknesses of each test method is important in
assessing which test provides the best evaluation of each disinfectant product. Studies have
previously performed statistical analyses of current FDA approved methods (72), including their
intra-laboratory reproducibility (73, 74), but have not done any analyses comparing the
methods head-to-head. This study presents a novel statistical model to test the efficacy of two
established testing methods.
Figures 11 and 12 show how the suspension and surface test methods predict sporicidal
activity of a solution as its activity declines with age. The suspension method produces
expected curves, showing the slow but predictable degradation of the disinfectant over time,
with its corresponding decreases in log reduction of the C. difficile spores. Data from the
surface method showed some unexpected trends (Fig 12). The initial increase in activity over
the first 3 days was unexpected. The slight increase in activity after day 10 was also unusual. As
the suspension method did not show these same trends, these anomalies could be due to the
variability inherent in this method. As stated previously, there may be differences in the
individual disks, or the way in which the spores dried on them, which allowed spores on these
surfaces to resist, or be to protected from, the disinfectant due to interference from other
spores in large clumps. It may be that some spores are able to reside safely in small marks and
defects in the metal, thus being protected from full contact with the disinfectant.
Our statistical analysis provides a prediction of the change in log reduction over time
according to method and contact time. This model predicts the suspension test log reductions
well (Fig 13A). However, the initial change from day 0 to day 1 did not correlate with predicted
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values for the 1 and 2-minute contact times. This may be explained in part by the drastic drop
in efficacy of the disinfectant 24 hours after activation. These linear models are helpful for
initial studies, and when considering a more complex models where additional covariates are
included. They provide a framework to understand the pattern of the test and the disinfectant
together over time.
For the surface test, when we compare the log reduction observed at day 0, which is
4.659, the predictive model underestimated this value by 0.832 (Fig 13B). In addition, as
indicated before, the log reduction values obtained from the surface method actually increased
during the first 3 days. This was not expected. These values then decreased steadily until day
10, at which point the values increased slightly until day 15. After day 15, there was a steady
decrease in activity with time until the termination of the experiment. Overall, the predicted
values were not as close to the observed as in the case of the suspension method. The linear
model using log reduction values may not be the best fit to model the data, but it does provide
relatively good predictions of how a disinfectant reduces the number of viable spore. There
could be other issues that alter the effectiveness of the linear model, such as, it is difficult to
calculate accurately the number of viable spore due to certain experimental limitations.
Increasing the test days and gathering more data points would make the linear model more
robust. Future non-linear models could also be helpful. As this is a new approach, the feedback
and results from similar publications in this area would benefit this hypothesis.
As mentioned previously, another reason for the lack of predictable trends in the
surface test may be due to the kinetics of the process. The disinfectant may not have full
physical access to the spores for the full contact time since it must cut through any biofilm and
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extracellular build up. This requires the disinfectant to complete two kinetic events before the
spores are killed. Due to this two-part kinetic activity, the surface test possesses additional
complications not present in the suspension test and does not represent a pure reaction of the
disinfectant against the spores.
Conclusion
We have developed a statistical model that compares the two methods, suspension and
surface, by the log reduction values produced over time. We have shown that the suspension
test produces log reduction values closer to the predicted values of the model compared to the
surface test. We conclude that the suspension test is better able to produce predictable data,
and is therefore more reliable in modeling disinfectant kill.
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Appendix
Statistical Analysis of Disinfectant Data
Abstract
In this report, we present the method that has been used to analyze the data collected
for a certain brand of disinfectant.
1. The Problem Setting
The purpose of this study was to determine the sporicidal activity and post-activation
use-life of a certain brand of disinfectant on C. difficile spores. Two methods had been used in
order to accomplish the task.
A. Surface Test - An EPA regulated method.
Key covariate:
(1) Contact time: 5 minutes. This is a degenerated covariate because there is only one level
for this variable.
(2) Days elapsed after opening the container: 0, 3, 6, 10, 15, 20.
B. Suspension Test - A comparable method.
Key covariate:
(1) Contact time: 1, 2, 5 minutes.
(2) Days elapsed after opening the container: 0, 3, 6, 10, 15, 20 days.
2. Method Used
The data has been divided into two sets and stored in two worksheets in Excel.
A. Surface Test Data
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B. Suspension Test Data

2.1. Models of Data
We considered a log linear model with Poisson distribution to model the counts of colonies in
each test setting. The model can be expressed as
Yij ∼Poisson(μYi)
and

′
log(μYi ) = log(E(Yij )) = Xi β + log(ni0),
where
•
•
•
•
•

Yij is the count of the number of spore colonies after treatment (applying of the
disinfectant on a certain day with a certain amount of contact time);
μYi is the mean count of spore colonies under the corresponding treatment;
Xi is the vector of the covariate(s);

β is the vector of the coefficients for the covariates;
ni0 is the initial count of spore colonies before treatment which is obtained through
titer.

3. Results
3.1. Models
SAS PROC GENMOD has been used to fit the models. Codes can be found in the Appendix
section. The outputs are presented below.
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A. Surface Test Data

log(μYi ) = −3.8275 + 0.0531Day + log(ni0),
B. Suspension Test Data

log(μYi ) = −6.1891 + 0.1750 × Day + 5.3503 × 1min + 3.3710 × 2min − 0.1419 × Day ∗ 1min −

0.0676 × Day ∗ 2min + log(ni0)
3.2. Comparing Two Models
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In order to compare two models obtained above, we adopted the likelihood ratio test to
determine which model is more likely to be a better estimate of the true model that fits data in
general.
SAS macro Vuong has been used to generate the result, which is attached as follows.
3.3. Notes about Vuong Non-nested Model Test
Vuong’s test requires that both models are fit using exactly the same set of response
values. However, in our experiment, we obtained two sets of response values, each under
surface and suspension test conditions. In order to make Vuong’s test available for our data, we
used the models from Proc Genmod to fill the “missing” part of the response values so that we
can get a single set of response values. This set of data can be found by run the SAS code in the
Appendix section.
4. Conclusion
Since the hypotheses we tested are:
H0 : Surface (1st) Model and Suspension (2nd) Model are equally close to the true model.
Hα : One of the models is closer to the true model.

Under the assumption that the null hypothesis is true, i.e. models are equally close to
the true model, the test statistic, which is a standardized likelihood ratio, would follow a normal
distribution. If the test statistic is negative and significant, the null hypothesis is rejected in
favor of the second model being closer to the true model. According to the SAS output from the
Vuong test macro, the test statistic is -5.8177. So we conclude that the model used to fit
suspension test is better.
5. Appendix
proc import datafile=”C:/Users/Jie/Documents/ BYU/Disinfectant/Data. xlsx”
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out=Carrierdata dbms=xlsx replace ; getnames= yes; sheet=”Carrier ”;
run ; Data carrier ;
set Carrierdata ; l n=l o g 1 0 ( T i t e r ) ; run ; proc print data=carrier ; run ;
proc import datafile=”C:/Users/Jie/Documents/ BYU/Disinfectant/Data. xlsx”
out=Suspensiondata dbms=xlsx replace ; getnames= yes; sheet=”Suspension ”;
run ; Data suspension ;
set Suspensiondata ; l n=l o g 1 0 ( T i t e r ) ; run ; proc print data=suspension ; run ;
proc genmod data=carrier plots=all ;
fwdlink link=log10( MEAN ); invlink ilink = 10∗∗( XBETA ); model Count = Day / dist=poisson
/∗ link=log ∗/ offset = ln obstats ;
output out=outcarrier p=pcarrier ; run ;
proc run ; proc
c l a s s fwdlink link=log10( MEAN ); invlink ilink = 10∗∗( XBETA ); model Count = Day
ContactTime Day∗ContactTime/ dist=poisson /∗ link=log ∗/ offset = ln obstats ; output
out=outsusp p=psusp ; run ; proc run ; data set p c a r r i e r = 1 0 ∗ ∗ ( − 3 . 8 2 7 5 + 0 . 0 5 3
1 ∗ D a y+ l n ) ; run ; proc print data=outsusp1 ; run ; data outcarrier1 ; set outcarrier ;
psusp=10∗∗(−6.1891+0.1750∗Day+ln ); run ; proc run ; data set run ;
print data=outcarrier ;
genmod data=suspension plots=all ; ContactTime ;
print data=outsusp ;
outsusp1 ; outsusp ;
print data=outcarrier1 ;
fits; outcarrier1 outsusp1 ;
proc print data=f i t s ; run ;
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%inc ”C:\Users\Jie\Documents\BYU\Disinfectant\vuong.sas”; %vuong(data=fits ,
response=Count,
model1=carrier , p1=pcarrier , dist1=poi , model2=suspension , p2=psusp , dist2=poi ,
nparm1=2, nparm2=6)
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